A study on five critically ill COVID-19 patients with acute respiratory failure and artificial ventilation found that all showed improvement after the administration of CP containing SARS-CoV-2 antibodies, combined with lopinavir/ritonavir and interferon treatment between days 10 and 22. This evidence concerns the gene CP and COVID-19.